CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or ...

Strong Memorial Hospital is among a select few in the U.S. offering Carvykti, a treatment for multiple myeloma, a cancer in ...

Multiple myeloma causes an expression of too much protein in a way that leads to excessive bone breakdown that isn’t properly balanced by new bone growth. How do multiple myeloma bone lesions feel?

Multiple myeloma — cancer of the white blood cells known as plasma cells — can cause a vast spectrum of symptoms as it progresses. But multiple myeloma often has no outward signs in its early ...

Around 1,500 people with multiple myeloma will benefit from belantamab mafodotin, used in combination with bortezomib and ...

Multiple myeloma is a kind of blood cancer that starts in plasma cells. ... Plasma cells, a type of white blood cell, help keep you healthy by making antibodies, proteins that fight infection.

Although multiple myeloma currently remains an incurable disease, ongoing research and innovation offer hope for improving survival rates and quality of life. 1 We are getting closer to potential ...

If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering the potential for disease ...

Multiple Myeloma (MM), a chronic and currently incurable hematologic malignancy, remains one of the most dynamic and competitive therapeutic landscapes in oncology. Originating from abnormal plasma ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products ...

Daratumumab targets the CD38 protein on multiple myeloma cells and induces tumor cell death. Tumors from patients in the trial are undergoing detailed molecular scrutiny.